Advanced SearchSearch Tips
Trans-arterial Chemo-Embolization in Treating Elderly Patients with Hepatocellular Carcinoma
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Trans-arterial Chemo-Embolization in Treating Elderly Patients with Hepatocellular Carcinoma
Zhang, Jian-Feng; Liu, Jun-Mao; Zhang, Nin; Du, Chao; Zheng, Qin;
  PDF(new window)
Background: This analysis was conducted to evaluate the efficacy and safety of Trans-arterial Chemo-Embolization (TACE) in treating Elderly patients with Hepatocellular Carcinoma (EHPC). Methods: Clinical studies evaluating the efficacy and safety of TACE on response and safety for patients with EHPC were identified by using a predefined search strategy. Pooled response rate of treatment were calculated. Results: In TACE based regimen, clinical studies which including patients with EHPC were considered eligible for the evaluation of response. And, in these TACE based treatments, pooled analysis suggested that, in all 288 patients whose response could be assessed, the pooled reponse rate was 29.5%(85/288) in TACE based treatment. The most commonly encountered TACE-related morbidity was liver function impairment. No grade III or IV renal or liver toxicity were observed. No treatment related death occurred in EHPC patients with TACE based treatments. Conclusion: This evidence based analysis suggests that TACE based treatments are associated with mild response rate and accepted toxicities for treating patients with EHPC.
TACE;elderly patients with Hepatocellular Carcinoma;
 Cited by
Biselli M, Forti P, Mucci F, et al (1997). Chemoembolization versus chemotherapy in elderly patients with unresectable hepatocellular carcinoma and contrast uptake as prognostic factor. J Gerontol A Biol Sci Med Sci, 52, 305-9.

Bruix J, Sherman M (2005). Management of hepatocellular carcinoma. Hepatology, 42, 1208-36. crossref(new window)

Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2. crossref(new window)

Bruix J, Castells A, Montanya X, et al (1994). Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology, 20, 643-50. crossref(new window)

Carr BI, Zajko A, Bron K, et al (1997). Phase II study of Spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin in the treatment of advanced-stage hepatocellular carcinoma: interim analysis. Semin Oncol, 24, 97-9.

Camma C, Schepis F, Orlando A, et al (2002). Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology, 224, 47-54. crossref(new window)

Cho SJ, Yoon JH, Hwang SS, et al (2007). Do young hepatocellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients? J Gastroenterol Hepatol, 22, 1226-31. crossref(new window)

Chuang VP, Wallace S, Soo CS, et al (1982). Terapeutic Ivalon embolization of hepatic tumors. AJR Am J Roentgenol, 138, 289-94. crossref(new window)

Cohen MJ, Bloom AI, Barak O, et al (2013). Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma. World J Gastroenterol, 19, 2521-8. crossref(new window)

Cohen MJ, Levy I, Barak O, et al (2014). Trans-arterial chemo-embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database. Liver Int, 34, 1109-17. crossref(new window)

Collier JD, Curless R, Bassendine MF, et al (1994). Clinical features and prognosis of hepatocellular carcinoma in Britain in relation to age. Age Ageing, 23, 22-7. crossref(new window)

Dhanasekaran R, Kooby DA, Staley CA, et al (2010). Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol, 101, 476-80.

Dohmen K, Shirahama M, Shigematsu H, et al (2004). Optimal treatment strategy for elderly patients with hepatocellular carcinoma. J Gastroenterol Hepatol, 19, 859-65. crossref(new window)

Earle CC, Venditti LN, Neumann PJ, et al (2000). Who gets chemotherapy for metastatic lung cancer? Chest, 117, 1239-46. crossref(new window)

European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer (2012). EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol, 56, 908-43. crossref(new window)

Fernandez-Ruiz M, Guerra-Vales JM, Llenas-Garcia J, et al (2008). Hepatocellular carcinoma in the elderly: clinical characteristics, survival analysis, and prognostic indicators in a cohort of Spanish patients older than 75 years. Rev Esp Enferm Dig, 100, 625-31.

Gunji T, Kawauchi N, Ohnishi S, et al (1992). Treatment of hepatocellular carcinoma associated with advanced cirrhosis by transcatheter arterial chemoembolization using autologous blood clot: a preliminary report. Hepatology, 15, 252-7. crossref(new window)

Hoshida Y, Ikeda K, Saito S, et al (1999). The efficacy and prognosis of transcatheter chemoembolization for hepatocellular carcinoma in the elderly. Nihon Shokakibyo Gakkai Zasshi, 96, 142-6.

Huang J, Li BK, Chen GH, et al (2009). Long-term outcomes and prognostic factors of elderly patients with hepatocellular carcinoma undergoing hepatectomy. J Gastrointest Surg, 13, 1627-35. crossref(new window)

Hutchins LF, Unger JM, Crowley JJ, et al (1999). Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med, 341, 2061-7. crossref(new window)

Kumar V, Fausto N, Abbas A (editors) (2003). Robbins & Cotran Pathologic Basis of Disease (7th ed.). Saunders. pp. 914-7.

Lammer J, Malagari K, Vogl T, et al (2010). Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol, 33, 41-52. crossref(new window)

Lee CR, Lim JH, Kim SH, et al (2012). A comparative analysis of hepatocellular carcinoma after hepatic resection in young versus elderly patients. J Gastrointest Surg, 16, 736-43.

Lewandowski RJ, Kulik LM, Riaz A, et al (2009). A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant, 9, 1920-8. crossref(new window)

Llovet JM, Bruix J (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology, 37, 429-42. crossref(new window)

Makuuchi M, Kokudo N, Arii S, et al (2008). Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res, 38, 37-51. crossref(new window)

Mirici-Cappa F, Gramenzi A, Santi V, et al (2010). Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut, 59, 387-96. crossref(new window)

Nicolini A, Martinetti L, Crespi S, et al (2010). Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol, 21, 327-32. crossref(new window)

Nishikawa H, Kita R, Kimura T, et al (2014). Transcatheter arterial chemoembolization for intermediate-stage hepatocellular carcinoma: clinical outcome and safety in elderly patients. J Cancer, 17, 590-7.

Omata M, Lesmana LA, Tateishi R, et al (2010). Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int, 4, 439-74. crossref(new window)

Oishi K, Itamoto T, Kobayashi T, et al (2009). Hepatectomy for hepatocellular carcinoma in elderly patients aged 75 years or more. J Gastrointest Surg, 13, 695-701. crossref(new window)

Pignata S, Gallo C, Daniele B, et al (2006). Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP). Crit Rev Oncol Hematol, 59, 243-9. crossref(new window)

Portolani N, Baiocchi GL, Coniglio A, et al (2011). Limited liver resection: a good indication for the treatment of hepatocellular carcinoma in elderly patients. Jpn J Clin Oncol, 41, 1358-65. crossref(new window)

Seeff LB, Hoofnagle JH (2006). Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene, 25, 3771-7. crossref(new window)

Thuluvath PJ, Guidinger MK, Fung JJ, et al (2010). Liver transplantation in the United States, 1999-2008. Am J Trans Plant, 2, 1003-19.

Tsukioka G, Kakizaki S, Sohara N, et al (2006). Hepatocellular carcinoma in extremely elderly patients: an analysis of clinical characteristics, prognosis and patient survival. World J Gastroenterol, 12, 48-53. crossref(new window)